Atria Investments LLC purchased a new position in CryoPort Inc (NASDAQ:CYRX) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 5,414 shares of the consumer goods maker’s stock, valued at approximately $404,000.
Other hedge funds have also added to or reduced their stakes in the company. BNP Paribas Arbitrage SA bought a new stake in CryoPort during the first quarter valued at $74,000. Bank of America Corp DE increased its stake in CryoPort by 92.3% during the fourth quarter. Bank of America Corp DE now owns 16,037 shares of the consumer goods maker’s stock valued at $176,000 after purchasing an additional 7,697 shares during the last quarter. Handelsinvest Investeringsforvaltning bought a new stake in CryoPort during the second quarter valued at $183,000. SG Americas Securities LLC bought a new stake in CryoPort during the second quarter valued at $249,000. Finally, Rhumbline Advisers increased its stake in CryoPort by 3.1% during the first quarter. Rhumbline Advisers now owns 34,962 shares of the consumer goods maker’s stock valued at $452,000 after purchasing an additional 1,043 shares during the last quarter. Hedge funds and other institutional investors own 60.92% of the company’s stock.
NASDAQ CYRX traded down $0.10 on Friday, hitting $19.18. 3,023 shares of the company were exchanged, compared to its average volume of 612,370. The firm has a market capitalization of $641.03 million, a P/E ratio of -61.37 and a beta of 0.88. CryoPort Inc has a twelve month low of $8.28 and a twelve month high of $25.02. The company has a debt-to-equity ratio of 0.17, a current ratio of 17.73 and a quick ratio of 17.68. The company’s 50 day moving average price is $21.48 and its 200-day moving average price is $16.99.
CryoPort (NASDAQ:CYRX) last issued its earnings results on Thursday, August 8th. The consumer goods maker reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). CryoPort had a negative return on equity of 17.32% and a negative net margin of 35.71%. The company had revenue of $8.46 million for the quarter, compared to the consensus estimate of $7.94 million. During the same quarter in the prior year, the company earned ($0.09) EPS. The firm’s quarterly revenue was up 82.7% on a year-over-year basis. As a group, equities analysts expect that CryoPort Inc will post -0.3 EPS for the current year.
Several research firms have recently commented on CYRX. Needham & Company LLC began coverage on shares of CryoPort in a research report on Monday, July 1st. They set a “buy” rating and a $22.00 price target for the company. B. Riley set a $26.00 price target on shares of CryoPort and gave the stock a “buy” rating in a research report on Friday, July 19th. Leerink Swann initiated coverage on shares of CryoPort in a research report on Monday, July 15th. They set a “buy” rating and a $24.00 price target for the company. Svb Leerink reaffirmed an “outperform” rating on shares of CryoPort in a report on Monday, July 15th. Finally, BidaskClub downgraded shares of CryoPort from a “buy” rating to a “hold” rating in a report on Wednesday, August 28th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. CryoPort has an average rating of “Buy” and an average price target of $24.00.
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
See Also: Commodities
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.